Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses

Lee, Seungho; Choi, Seohee; Kim, Sang Yong; Yun, Mijin; Kim, Wook

doi:10.5230/jgc.2017.17.e43

Cited by 20 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reasonable to hypothesize that tumor microenvironment -especially the amount of stromal TILscould affect the FDG uptake and distribution of malignant lesions. In gastric cancer [28] and in case of non-small cell lung cancer [29] a positive correlation was already described between the presence of TILs and FDG-uptake in case of routinely used static FDG-PET/CT imaging. Regarding breast cancer, this question was only assessed indirectly, in the recently published study of Fujii et al [30], who found a relationship between higher neutrophil granulocyte/lymphocyte ratio (i.e.…”

Section: Discussionmentioning

confidence: 80%

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations

Kajáry

Lengyel

Tőkés

et al. 2019

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic softwarebased correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogenreceptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in nodenegative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration.

show abstract

Section: Discussionmentioning

confidence: 80%

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations

Kajáry

Lengyel

Tőkés

et al. 2019

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…The advantage of using paraffin-embedded tissue blocks is that the long-term outcome of the treated patients is already known. The tumor microenvironment is assessed by evaluating the lymphocytes [133134135], tumor-associated macrophages [72], and myeloid-derived suppressor cells [136].…”

Section: Approaches For Evaluating Inflammatory Parametersmentioning

confidence: 99%

Biomarkers for Evaluating the Inflammation Status in Patients with Cancer

Güner

Kim

2019

J Gastric Cancer

Self Cite

View full text Add to dashboard Cite

Inflammation can be a causative factor for carcinogenesis or can result from a consequence of cancer progression. Moreover, cancer therapeutic interventions can also induce an inflammatory response. Various inflammatory parameters are used to assess the inflammatory status during cancer treatment. It is important to select the most optimal biomarker among these parameters. Additionally, suitable biomarkers must be examined if there are no known parameters. We briefly reviewed the published literature for the use of inflammatory parameters in the treatment of patients with cancer. Most studies on inflammation evaluated the correlation between host characteristics, effect of interventions, and clinical outcomes. Additionally, the levels of C-reactive protein, albumin, lymphocytes, and platelets were the most commonly used laboratory parameters, either independently or in combination with other laboratory parameters and clinical characteristics. Furthermore, the immune parameters are classically examined using flow cytometry, immunohistochemical staining, and enzymelinked immunosorbent assay techniques. However, gene expression profiling can aid in assessing the overall peri-interventional immune status. The checklists of guidelines, such as STAndards for Reporting of Diagnostic accuracy and REporting recommendations for tumor MARKer prognostic studies should be considered when designing studies to investigate the inflammatory parameters. Finally, the data should be interpreted after adjusting for clinically important variables, such as age and cancer stage.

show abstract

“…We consider that this issue was due to the small sample sizes in previous reports. As FDG-PET visualizes the glycolytic activity of a tumor, it is likely that both a large tumor size and a high proliferation potential result in increased FDG uptake [12,13]. Moreover, because the risk grades of GISTs are defined based on the tumor size and mitotic index, a positive correlation between the SUVmax and risk grade seems reasonable.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors

Iwamuro

Miyahara

Sakaguchi

et al. 2020

JCM

View full text Add to dashboard Cite

There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. The correlation between the SUVmax and mitotic index was also investigated in GISTs. The SUVmax (mean ± standard deviation) was 0.5 ± 0.6 in very low-risk GISTs (n = 42), 2.1 ± 0.7 in low-risk GISTs (n = 26), 4.9 ± 0.8 in intermediate-risk GISTs (n = 22), 12.3 ± 0.8 in high-risk GISTs (n = 20), 1.0 ± 1.0 in leiomyomas (n = 15), 6.9 ± 1.2 in schwannomas (n = 10), and 3.5 in a leiomyosarcoma (n = 1). The SUVmax of GISTs with an undetermined risk classification was 4.2 ± 1.3 (n = 8). Linear associations were observed between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax of GISTs with a high mitotic index was significantly higher than that of GISTs with a low mitotic index (9.6 ± 7.6 vs. 2.4 ± 4.2). In conclusion, we observed positive correlations between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax also positively correlated with the mitotic index and risk grade in GISTs. Schwannomas showed a higher FDG uptake than GISTs and leiomyomas.

show abstract

Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses

Cited by 20 publications

References 40 publications

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations

Biomarkers for Evaluating the Inflammation Status in Patients with Cancer

Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors

Contact Info

Product

Resources

About